Hypothesis

Chronic pharmacological suppression of nociceptor activity in midlife shifts the balance from adaptive hormetic signaling to maladaptive, splice‑driven CGRP isoform expression that drives cellular senescence and inflammaging, thereby accelerating biological aging.

Mechanistic Rationale

1. Nociceptor hormesis vs pathology – Acute TRPV1‑dependent pain activates cAMP‑PKA‑CREB pathways that promote mitochondrial Ca²⁺ uptake, autophagy (via AMPK) and transient CGRP release, which at low levels supports tissue repair and immune surveillance [2]. With age, descending inhibitory tone wanes and spinal LTP‑like sensitization establishes a maladaptive pain state [3].
2. Pharmacological blunt‑force – NSAIDs or opioids given after this point silence both the residual hormetic cAMP‑PKA‑CREB burst and the maladaptive spike, but they do not reverse the underlying splice‑regulatory drift that favors exon‑skipping of the Calca (CGRP) pre‑mRNA, producing a CGRP isoform lacking the C‑terminal amide required for rapid clearance [4]. This isoform accumulates, sustains low‑grade PKA activation in peripheral targets (pancreatic islets, macrophages), and chronically suppresses AMPK‑ULK1 autophagy flux.
3. Splicing‑centric link to longevity – Aging‑associated decline in SR‑protein activity and rise in hnRNP‑mediated exon skipping shifts Calca splicing toward the unstable isoform, a process mirrored in other longevity genes (e.g., Mapk1, Insr) [5]. By dampening nociceptor firing, analgesics reduce activity‑dependent signaling that normally promotes inclusion of the exon encoding the clearance‑competent CGRP tail, thereby locking cells into a senescent‑associated secretory phenotype (SASP) marked by p16^Ink4a, SASP cytokines, and reduced LC3‑II.

Testable Predictions

• Mice receiving chronic morphine (or ibuprofen) from 12 months of age will show:
  • ↑ pancreatic Calca exon‑skipped isoform / total CGRP ratio (RT‑PCR).
  • ↓ p‑AMPK (Thr172) and p‑ULK1 (Ser555) levels in islets and macrophages.
  • ↑ p16^Ink4a‑positive cells and SASP cytokines (IL‑6, IL‑1β) in pancreas and spleen.
  • Impaired glucose tolerance correlating with isoform shift.
• Rescue experiments:
  • Intrathecal delivery of a splice‑switching antisense oligonucleotide (SSO) forcing inclusion of the exon encoding the CGRP C‑terminal amide will normalize isoform ratio, restore AMPK activity, and reduce senescence markers despite ongoing analgesic exposure.
  • Alternatively, low‑dose TRPV1 agonist (capsazepine‑free) given intermittently will reinstate activity‑dependent exon inclusion and mitigate the pro‑senescent shift.

Experimental Design

1. Cohorts (n=10 per group): young (3 mo) untreated, middle‑aged (12 mo) untreated, middle‑aged + chronic morphine (10 mg/kg/day, s.c. pump) for 4 mo, middle‑aged + morphine + SSO, middle‑aged + morphine + intermittent capsaicin.
2. Readouts (at 16 mo):
   • Isoform‑specific qPCR for Calca (exon 4 inclusion vs skip).
   • Western blot for p‑AMPK, p‑ULK1, LC3‑II/I, p16^Ink4a.
   • ELISA for CGRP, IL‑6, IL‑1β in plasma and tissue homogenates.
   • Metabolic: GTT, insulin tolerance test.
   • Histology: immunostaining for SASP markers.
3. Statistical analysis: Two‑way ANOVA with post‑hoc Tukey; significance set at p<0.05.

Falsifiability

If chronic analgesic treatment does not alter the Calca splicing ratio, fails to change AMPK/ULK1 phosphorylation, and does not increase senescence markers relative to untreated controls, the hypothesis is refuted. Conversely, if the SSO rescue fails to restore AMPK activity or reduce senescence despite correcting the isoform, the causal link between CGRP splicing and analgesic‑driven aging would be questioned.

This framework ties together nociceptor hormesis, age‑dependent splicing dysregulation, and the unintended consequences of blunt analgesic silencing, offering a concrete, falsifiable route to test whether we are indeed silencing a longevity signal.